Xenon Pharmaceuticals XENE Increase (Decrease) in Other Receivables

Increase (Decrease) in Other Receivables at other companies

ACM ResearchACMR

$406K+106%

State StreetSTT

$313M+26.7%

Moelis & CompanyMC

-$347K-102%

GE VernovaGEV

-$610M+33.6%

DaVitaDVA

$22.77M-44.6%

ShopifySHOP

$54.75M+48.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$112.3M-54.4%

Net income-$102.3M-57.3%

EPS (diluted)-$1.17-41.0%

Balance sheet

See full

Cash & equivalents$545.9M+368%

Total debt$7.5M-13.6%

Total equity$1.3B+90.0%

Total assets$1.4B+86.6%

Cash flow

See full

Operating cash flow-$88.9M-44.2%

CapEx$133.0K+209%

Free cash flow-$89.0M-44.3%

Valuation

See full

Market cap$5.11B+116%

Profitability

See full

Operating margin-4,974.3%—

Net margin-4,612.1%—

FCF margin-3,732.2%—

Returns & leverage

See full

Return on equity-37.5%+8.7pp

Debt / equity0×0.0×

Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's increase (decrease) in other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xenon Pharmaceuticals's increase (decrease) in other receivables?: Xenon Pharmaceuticals (XENE) reported increase (decrease) in other receivables of -$205K in Q1 2026.
How has Xenon Pharmaceuticals's increase (decrease) in other receivables changed year-over-year?: Xenon Pharmaceuticals's increase (decrease) in other receivables decreased by 102.9% year-over-year, from $7.18M to -$205K.